Comments
Pharma major Dr Reddy's Laboratories has launched its anti-allergy drug, Fexofenadine HCl tablets, in the US market.
The Hyderabad-based company had received approval from the US Food and Drug Administration for its Abbreviated New Drug Application for Fexofenadine HCl tablets.
Dr Reddy's would market the product under store brand labels in the US market. It would be sold over the counter, according to a release issued here on Thursday. The product is bioequivalent version of Sanofi-Aventis' Allegra tablets.
The Fexofenadine HCl market had brand and generic sales of approximately $452 million for the 12 months ending December 31, 2010, according to IMS Health.
In January, the US District Court of New Jersey had cleared the decks for the launch of the drug by Dr Reddy's in the US.
The US Court had also ordered Sanofi-Aventis and Albany Molecular Research, which had earlier obtained an injunction against launching of the drug, to post a security of $ 40 million with the Court towards the likelihood that the injunction had been wrongfully granted.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.